TABLE 2.

Contributions to changes in pharmaceutical spending by 2-year periods, overall and by sector (%).

	2010–2011 vs. 2012–2013	2012–2013 vs. 2014–2015	2014–2015 vs. 2016–2017	2016–2017 vs. 2018–2019	Annual average	(Change)
Total Relative increment	−0.74	7.82	16.40	16.09	4.9	(100)
New drugs	1.58	2.19	2.69	1.70	1.0	(21)
Continued drugs	−2.22	5.81	13.77	14.67	4.0	(81)
Price (P)	−16.34	−6.51	−2.19	−3.04	−3.5	(−71)
Mixed effect in the main active ingredient	−1.36	−1.24	−1.09	−0.22	−0.5	(−10)
Quantity (Q)	15.48	13.56	17.05	17.92	8	(162)
Abandoned drugs	−0.10	−0.17	−0.06	−0.27	−0.1	(−2)
Inpatient relative increment	−6.05	1.92	10.77	10.89	2.2	(100)
New drugs	0.62	3.27	1.68	2.64	1.0	(47)
Continued drugs	−6.48	−1.16	9.21	8.48	1.3	(57)
Price (P)	−15.62	−7.45	−4.14	−3.58	−3.8	(−176)
Mixed effect in the main active ingredient	−0.67	−0.45	−0.93	0.01	−0.3	(−12)
Quantity (Q)	9.81	6.74	14.28	12.05	5.4	(245)
Abandoned drugs	−0.19	−0.19	−0.12	−0.23	−0.1	(−4)
Outpatient Relative increment	0.31	8.91	17.38	16.94	5.4	(100)
New drugs	2.09	2.01	4.61	1.56	1.3	(24)
Continued drugs	−1.58	7.10	12.82	15.69	4.3	(78)
Price (P)	−16.80	−6.31	−1.58	−2.94	−3.5	(−63)
Mixed effect in the main active ingredient	−1.50	−1.40	−1.19	−0.24	−0.5	(−10)
Quantity (Q)	16.72	14.81	15.59	18.87	8.2	(152)
Abandoned drugs	−0.20	−0.21	−0.05	−0.31	−0.1	(−2)

Changes were calculated as the annual average.